SS

Shravya Spandana Kesanakurthy

Active Director Director DIN 09601598
DIN 09601598 First appointment May 2022 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since May 2022
Shareholding value β€’β€’β€’β€’ Premium profile

About Shravya Spandana Kesanakurthy

Data last updated:

Shravya Spandana Kesanakurthy is a Director at Curevet Formulations Private Limited (since 2022). The company operates in Chemicals.

DIN 09601598
Primary Designation Director
Industry Chemicals
First Appointment 10 May 2022
Oldest Company Age 4 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Curevet Formulations Private Limited U24290TG2022PTC162497
Director10 May 20222022Active

Board colleagues of Shravya Spandana Kesanakurthy

Directorship timeline

Open interactive timeline →
Curevet Formulations Private Limited
Premium access

Shareholding and investment profile for Shravya Spandana Kesanakurthy

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Shravya Spandana Kesanakurthy

Shravya Spandana Kesanakurthy currently holds 1 directorship: Curevet Formulations Private Limited (Director, since 10 May 2022).

Shravya Spandana Kesanakurthy was first appointed on 10 May 2022 as Director at Curevet Formulations Private Limited.

The current boards of Shravya Spandana Kesanakurthy's companies include Amulya Kesanakurthy (Curevet Formulations Private Limited), Srinivasa Babu Kesanakurthy (Curevet Formulations Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available